Longest survival follow-up reported to date for a Phase III trial in this setting<\/i><\/b><\/p>\n
WILMINGTON, Del.–(BUSINESS WIRE<\/a>)– \nThese results from HIMALAYA will be presented today at the 2023 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain (abstract #SO-15).<\/p>\n \nAt four years of follow-up, these latest data show that a single priming dose of IMJUDO added to IMFINZI, called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab),reduced the risk of death by 22% compared to sorafenib (based on a hazard ratio [HR] of 0.78; 95% confidence interval [CI] 0.67-0.92; 78% data maturity). An estimated 25.2% of patients treated with the STRIDE regimen were alive at four years versus 15.1% for those treated with sorafenib. An ad-hoc exploratory analysis showed that the treatment effects of the STRIDE regimen versus sorafenib were consistent across all clinically relevant subgroups of patients, as well as those surviving at least three years, regardless of the underlying disease cause (hepatitis B virus [HBV], hepatitis C virus [HCV] or nonviral) or other baseline demographics.<\/p>\n \nBruno Sangro, MD, PhD, Director of the Liver Unit and Professor of Internal Medicine at Cl\u00ednica Universidad de Navarra, Pamplona, Spain and a lead investigator in the trial, said: \u201cHistorically, only seven percent of patients with advanced liver cancer have survived five years, making the HIMALAYA long-term survival data especially meaningful. One in four patients treated with the STRIDE regimen were still alive at four years, reinforcing this novel regimen as a standard of care in this setting.\u201d<\/p>\n \nSusan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: \u201cThe remarkable four-year survival benefit shown with IMFINZIand IMJUDOin this advanced liver cancer setting supports the use of the STRIDE regimen to treat a broad, eligible patient population globally. These latest results from HIMALAYA are part of a series of clinical trials aiming to deliver innovative treatments for patients at different stages of liver cancer.\u201d<\/p>\n Summary of updated results: HIMALAYA<\/b><\/p>\n
\nUpdated results from the HIMALAYA Phase III trial showed AstraZeneca\u2019s IMFINZI\u00ae<\/sup> (durvalumab) plus IMJUDO\u00ae<\/sup>(tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230629262663\/en\/484259\/3\/Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n